Q3 2025 Earnings Call Transcript November 13, 2025 Vaxart, Inc. beats earnings expectations. Reported EPS is $-0.04, expectations were $-0.07. Operator: Greetings, and welcome to the Vaxart Business ...

FOR some people, it starts with a scratchy throat followed by a tickly cough. For others, a headache comes first, before a ...

With this year’s ‘quad-demic’ of flu, Covid, RSV and norovirus starting to surge, here are the symptoms to watch for and how ...

Received FDA IND clearance to evaluate CDI-988 as both norovirus preventive and treatmentExpects to initiate CDI-988 Phase 1b ...

Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollm ...

Entered into an exclusive license agreement with Dynavax for the Company’s COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed ...

The UK Health Security Agency (UKHSA) has published the most recent data on norovirus, often referred to as the "winter ...

Norovirus causes vomiting and diarrhoea. While it's unpleasant, it typically clears up in about two days, according to NHS ...

Norovirus triggers symptoms such as vomiting and diarrhoea. While it can be extremely unpleasant, it typically resolves ...

Louisville Metro Health and Wellness report public health researchers have detected an increase in norovirus levels in ...

Leading children's doctors have urged parents to get their children the nasal spray that protects against flu amid concerns ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...